Imipramine
Generic name: Pronounced as (im ip' ra meen)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 09/15/2018
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I know about STORAGE and DISPOSAL of this medication?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
IMPORTANT WARNING
A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as imipramine during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take imipramine except to prevent bedwetting, but in some cases, a doctor may decide that imipramine is the best medication to treat a child's condition.
You should know that your mental health may change in unexpected ways when you take imipramine or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.
Your healthcare provider will want to see you often while you are taking imipramine, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.
The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with imipramine. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273.
No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.
Why is this medication prescribed?
Imipramine tablets and capsules are used to treat depression. Imipramine tablets are also used to prevent bedwetting in children. Imipramine is in a class of medications called tricyclic antidepressants. It treats depression by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance. There is not enough information to explain how imipramine prevents bedwetting.
How should this medicine be used?
Imipramine comes as a tablet and a capsule to take by mouth. When imipramine tablets or capsules are used to treat depression, they are usually taken one or more times a day and may be taken with or without food. When imipramine tablets are used to prevent bedwetting in children, they are usually taken one hour before bedtime. Children who wet the bed early in the evening may be given one dose in the mid-afternoon and another dose at bedtime. Try to take imipramine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take imipramine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Your doctor may start you on a low dose of imipramine and gradually increase your dose.
It may take 1-3 weeks or longer for you to feel the full benefit of imipramine. Continue to take imipramine even if you feel well. Do not stop taking imipramine without talking to your doctor. Your doctor will probably want to decrease your dose gradually.
Other uses for this medicine
Imipramine is also used occasionally to treat eating disorders and panic disorders. Talk to your doctor about the possible risks of using this medication for your condition.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking imipramine,
-
tell your doctor and pharmacist if you are allergic to imipramine, any other medications, or any of the ingredients in imipramine tablets or capsules. Ask your doctor or pharmacist for a list of the ingredients.
-
tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking an MAO inhibitor within the past 14 days. Your doctor will probably tell you not to take imipramine. If you stop taking imipramine, you should wait at least 14 days before you start to take an MAO inhibitor.
-
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); antihistamines; cimetidine (Tagamet); flecainide (Tambocor); levodopa (Sinemet, Larodopa); lithium (Eskalith, Lithobid); medication for high blood pressure, mental illness, nausea, seizures, Parkinson's disease, asthma, colds, or allergies; methylphenidate (Ritalin); muscle relaxants; propafenone (Rhythmol); quinidine; sedatives; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); sleeping pills; thyroid medications; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Your doctor may tell you not to take imipramine if you have taken fluoxetine in the past 5 weeks.
-
tell your doctor if you have recently had a heart attack. Your doctor may tell you not to take imipramine.
-
tell your doctor if you are being treated with electroshock therapy (procedure in which small electric shocks are administered to the brain to treat certain mental illnesses), and if you have or have ever had an enlarged prostate (a male reproductive gland), difficulty urinating, seizures, an overactive thyroid gland, or liver, kidney, or heart disease.
-
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking imipramine, call your doctor.
-
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking imipramine.
-
you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
-
remember that alcohol can add to the drowsiness caused by this medication.
-
tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.
-
plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Imipramine may make your skin sensitive to sunlight.
-
talk to your doctor about the risks and benefits of taking imipramine if you are 65 years of age or older. Older adults should not usually take imipramine because it is not as safe and effective as other medications that can be used to treat the same condition.
-
you should know that imipramine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What should I do if I forget a dose?
Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule.
What side effects can this medication cause?
-
Imipramine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
nausea
-
drowsiness
-
weakness or tiredness
-
excitement or anxiety
-
nightmares
-
dry mouth
-
skin more sensitive to sunlight than usual
-
changes in appetite or weight
-
constipation
-
difficulty urinating
-
frequent urination
-
changes in sex drive or ability
-
excessive sweating
-
-
Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:
-
jaw, neck, and back muscle spasms
-
slow or difficult speech
-
shuffling walk
-
uncontrollable shaking of a part of the body
-
fever, sore throat, or other signs of infection
-
difficulty breathing or swallowing
-
severe rash
-
yellowing of the skin or eyes
-
irregular heartbeat
-
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
-
Imipramine may cause other side effects. Tell your doctor if you have any unusual problems while you are taking this medication.
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
What OTHER INFORMATION should I know?
Keep all appointments with your doctor.
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Moxifloxacin | Moxifloxacin The metabolism of Imipramine can be decreased when combined with Moxifloxacin. |
Repaglinide | Repaglinide Imipramine may decrease the hypoglycemic activities of Repaglinide. |
Insulin Glargine (rDNA origin) Injection | Insulin Glargine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glargine. |
Leflunomide | Leflunomide The serum concentration of Imipramine can be decreased when it is combined with Leflunomide. |
Delavirdine | Delavirdine The metabolism of Imipramine can be decreased when combined with Delavirdine. |
Nevirapine | Nevirapine The metabolism of Imipramine can be decreased when combined with Nevirapine. |
Atorvastatin | Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Imipramine. |
Dolasetron | Dolasetron The metabolism of Imipramine can be decreased when combined with Dolasetron. |
Aminophylline | Aminophylline The metabolism of Aminophylline can be decreased when combined with Imipramine. |
Anagrelide | Anagrelide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Anagrelide. |
Bisacodyl | Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Imipramine. |
Candesartan | Candesartan Imipramine may decrease the antihypertensive activities of Candesartan. |
Cilostazol | Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Imipramine. |
Clopidogrel | Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Imipramine resulting in a loss in efficacy. |
Diphenoxylate | Diphenoxylate The risk or severity of adverse effects can be increased when Imipramine is combined with Diphenoxylate. |
Erythromycin and Sulfisoxazole | Erythromycin and Sulfisoxazole The serum concentration of Imipramine can be increased when it is combined with Erythromycin. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Imipramine. |
Fenofibrate | Fenofibrate The metabolism of Imipramine can be decreased when combined with Fenofibrate. |
Guanfacine | Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Magnesium Hydroxide | Magnesium Hydroxide Imipramine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
Magnesium Oxide | Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Imipramine. |
Methylergonovine | Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Imipramine. |
Miglitol | Miglitol Imipramine may decrease the hypoglycemic activities of Miglitol. |
Mycophenolate | Mycophenolate Imipramine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. |
Naratriptan | Naratriptan The risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan. |
Olsalazine | Olsalazine Imipramine may decrease the excretion rate of Olsalazine which could result in a higher serum level. |
Paregoric | Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine. |
Penbutolol | Penbutolol The metabolism of Imipramine can be decreased when combined with Acebutolol. |
Pentazocine | Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine. |
Polyethylene glycol-electrolyte solution (PEG-ES) | Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine. |
Potassium | Potassium Potassium may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Prednisone | Prednisone Imipramine may decrease the excretion rate of Prednisone which could result in a higher serum level. |
Psyllium | Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Imipramine. |
Ranitidine | Ranitidine The metabolism of Ranitidine can be decreased when combined with Imipramine. |
Reserpine | Reserpine The serum concentration of Reserpine can be increased when it is combined with Imipramine. |
Rizatriptan | Rizatriptan Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Sumatriptan | Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Tacrolimus | Tacrolimus The serum concentration of Imipramine can be increased when it is combined with Tacrolimus. |
Tizanidine | Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Imipramine. |
Triamcinolone | Triamcinolone The metabolism of Imipramine can be increased when combined with Triamcinolone. |
Zolmitriptan | Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Imipramine. |
Ampicillin Injection | Ampicillin Injection Ampicillin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Doxycycline Injection | Doxycycline Injection Doxycycline may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Famotidine Injection | Famotidine Injection The metabolism of Imipramine can be decreased when combined with Famotidine. |
Fluconazole Injection | Fluconazole Injection The serum concentration of Imipramine can be increased when it is combined with Fluconazole. |
Foscarnet Injection | Foscarnet Injection Foscarnet may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Hydromorphone Injection | Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Imipramine. |
Interferon Beta-1b Injection | Interferon Beta-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1b. |
Interferon Gamma-1b Injection | Interferon Gamma-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon gamma-1b. |
Levofloxacin Injection | Levofloxacin Injection The metabolism of Imipramine can be decreased when combined with Levofloxacin. |
Meperidine Injection | Meperidine Injection The metabolism of Imipramine can be decreased when combined with Meperidine. |
Metoclopramide Injection | Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Imipramine. |
Metronidazole Injection | Metronidazole Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Metronidazole. |
Morphine Injection | Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine. |
Pamidronate Injection | Pamidronate Injection Pamidronic acid may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Vancomycin Injection | Vancomycin Injection Imipramine may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
Altretamine | Altretamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine. |
Cefuroxime | Cefuroxime Cefuroxime may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cyclosporine | Cyclosporine The metabolism of Imipramine can be decreased when combined with Cyclosporine. |
Ondansetron | Ondansetron The metabolism of Ondansetron can be decreased when combined with Imipramine. |
Granisetron | Granisetron The risk or severity of QTc prolongation can be increased when Imipramine is combined with Granisetron. |
Torsemide | Torsemide Imipramine may increase the excretion rate of Torasemide which could result in a lower serum level and potentially a reduction in efficacy. |
Alosetron | Alosetron The metabolism of Imipramine can be decreased when combined with Alosetron. |
Dofetilide | Dofetilide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Dofetilide. |
Entacapone | Entacapone The metabolism of Imipramine can be decreased when combined with Entacapone. |
Eprosartan | Eprosartan Imipramine may decrease the antihypertensive activities of Eprosartan. |
Hydroxychloroquine | Hydroxychloroquine The metabolism of Imipramine can be decreased when combined with Hydroxychloroquine. |
Meloxicam | Meloxicam Imipramine may decrease the excretion rate of Meloxicam which could result in a higher serum level. |
Oxcarbazepine | Oxcarbazepine The metabolism of Imipramine can be decreased when combined with Oxcarbazepine. |
Pantoprazole | Pantoprazole The metabolism of Imipramine can be decreased when combined with Pantoprazole. |
Telmisartan | Telmisartan The metabolism of Imipramine can be decreased when combined with Telmisartan. |
Temozolomide | Temozolomide Imipramine may decrease the excretion rate of Temozolomide which could result in a higher serum level. |
Zaleplon | Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Anakinra | Anakinra The metabolism of Imipramine can be increased when combined with Anakinra. |
Desloratadine | Desloratadine Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Linezolid | Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Imipramine. |
Rivastigmine | Rivastigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Rivastigmine. |
Trimipramine | Trimipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine. |
Etanercept Injection | Etanercept Injection The metabolism of Imipramine can be increased when combined with Etanercept. |
Glycopyrrolate | Glycopyrrolate The risk or severity of adverse effects can be increased when Imipramine is combined with Glycopyrronium. |
Modafinil | Modafinil The metabolism of Imipramine can be decreased when combined with Modafinil. |
Perindopril | Perindopril Imipramine may decrease the antihypertensive activities of Perindopril. |
Tenofovir | Tenofovir Tenofovir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Choline Magnesium Trisalicylate | Choline Magnesium Trisalicylate Imipramine may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level. |
Sirolimus | Sirolimus The metabolism of Sirolimus can be decreased when combined with Imipramine. |
Dutasteride | Dutasteride The risk or severity of hypertension can be increased when Imipramine is combined with Dutasteride. |
Epinephrine Injection | Epinephrine Injection Imipramine may increase the vasopressor activities of Epinephrine. |
Eplerenone | Eplerenone Imipramine may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy. |
Escitalopram | Escitalopram The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Escitalopram. |
Olmesartan | Olmesartan Imipramine may decrease the antihypertensive activities of Olmesartan. |
Zonisamide | Zonisamide The serum concentration of Imipramine can be increased when it is combined with Zonisamide. |
Adalimumab Injection | Adalimumab Injection The metabolism of Imipramine can be increased when combined with Adalimumab. |
Aripiprazole | Aripiprazole Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole. |
Atomoxetine | Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Imipramine. |
Dexmethylphenidate | Dexmethylphenidate The serum concentration of Imipramine can be increased when it is combined with Dexmethylphenidate. |
Atazanavir | Atazanavir Atazanavir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Almotriptan | Almotriptan The metabolism of Imipramine can be decreased when combined with Almotriptan. |
Eletriptan | Eletriptan The metabolism of Imipramine can be decreased when combined with Eletriptan. |
Mefloquine | Mefloquine The metabolism of Imipramine can be decreased when combined with Mefloquine. |
Polyethylene Glycol 3350 | Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine. |
Vardenafil | Vardenafil The serum concentration of Imipramine can be increased when it is combined with Vardenafil. |
Alfuzosin | Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Aprepitant | Aprepitant The metabolism of Imipramine can be decreased when combined with Aprepitant. |
Emtricitabine | Emtricitabine Imipramine may decrease the excretion rate of Emtricitabine which could result in a higher serum level. |
Interferon Beta-1a Subcutaneous Injection | Interferon Beta-1a Subcutaneous Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1a. |
Memantine | Memantine The metabolism of Imipramine can be decreased when combined with Memantine. |
Tegaserod | Tegaserod The metabolism of Imipramine can be decreased when combined with Tegaserod. |
Tadalafil | Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Imipramine is combined with Tadalafil. |
Frovatriptan | Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Imipramine. |
Gemifloxacin | Gemifloxacin The metabolism of Imipramine can be decreased when combined with Gemifloxacin. |
Progesterone | Progesterone The metabolism of Imipramine can be decreased when combined with Progesterone. |
Apomorphine Injection | Apomorphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Apomorphine. |
Infliximab Injection | Infliximab Injection The metabolism of Imipramine can be increased when combined with Infliximab. |
Protriptyline | Protriptyline The metabolism of Imipramine can be decreased when combined with Protriptyline. |
Rifaximin | Rifaximin The metabolism of Imipramine can be increased when combined with Rifaximin. |
Duloxetine | Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Imipramine is combined with Duloxetine. |
Norethindrone | Norethindrone The metabolism of Norethisterone can be increased when combined with Imipramine. |
Tinidazole | Tinidazole Imipramine may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
Trospium | Trospium The metabolism of Trospium can be decreased when combined with Imipramine. |
Bosentan | Bosentan Imipramine may decrease the antihypertensive activities of Bosentan. |
Cefditoren | Cefditoren Imipramine may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
Cinacalcet | Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Imipramine. |
Cyanocobalamin Injection | Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Erlotinib | Erlotinib The metabolism of Imipramine can be decreased when combined with Erlotinib. |
Eszopiclone | Eszopiclone The risk or severity of CNS depression can be increased when Imipramine is combined with Eszopiclone. |
Ganciclovir | Ganciclovir Imipramine may decrease the excretion rate of Ganciclovir which could result in a higher serum level. |
Insulin Aspart (rDNA Origin) Injection | Insulin Aspart (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin aspart. |
Ribavirin | Ribavirin Imipramine may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
Solifenacin | Solifenacin The metabolism of Imipramine can be decreased when combined with Solifenacin. |
Valganciclovir | Valganciclovir Imipramine may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
Voriconazole | Voriconazole The metabolism of Imipramine can be decreased when combined with Voriconazole. |
Adefovir | Adefovir Adefovir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Dextroamphetamine | Dextroamphetamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine. |
Entecavir | Entecavir The metabolism of Entecavir can be decreased when combined with Imipramine. |
Peginterferon Alfa-2a Injection | Peginterferon Alfa-2a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b. |
Pramlintide Injection | Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Imipramine. |
Sodium Oxybate | Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Exenatide Injection | Exenatide Injection Imipramine may decrease the hypoglycemic activities of Exenatide. |
Ibandronate | Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine. |
Isocarboxazid | Isocarboxazid Imipramine may increase the serotonergic activities of Isocarboxazid. |
Ramelteon | Ramelteon The metabolism of Imipramine can be decreased when combined with Ramelteon. |
Darifenacin | Darifenacin The metabolism of Darifenacin can be decreased when combined with Imipramine. |
Fentanyl | Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Imipramine. |
Pregabalin | Pregabalin The therapeutic efficacy of Imipramine can be increased when used in combination with Pregabalin. |
Deferasirox | Deferasirox The serum concentration of Imipramine can be increased when it is combined with Deferasirox. |
Phenylephrine | Phenylephrine Imipramine may increase the vasopressor activities of Phenylephrine. |
Tipranavir | Tipranavir The metabolism of Imipramine can be decreased when combined with Tipranavir. |
Felbamate | Felbamate The metabolism of Imipramine can be decreased when combined with Felbamate. |
Insulin Detemir (rDNA Origin) Injection | Insulin Detemir (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin detemir. |
Ranolazine | Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Imipramine. |
Abatacept Injection | Abatacept Injection The metabolism of Imipramine can be increased when combined with Abatacept. |
Rasagiline | Rasagiline Rasagiline may increase the serotonergic activities of Imipramine. |
Imatinib | Imatinib The metabolism of Imipramine can be decreased when combined with Imatinib. |
Sitagliptin | Sitagliptin Imipramine may decrease the hypoglycemic activities of Sitagliptin. |
Varenicline | Varenicline The excretion of Varenicline can be decreased when combined with Imipramine. |
Gefitinib | Gefitinib The metabolism of Imipramine can be decreased when combined with Gefitinib. |
Albuterol | Albuterol The risk or severity of QTc prolongation can be increased when Imipramine is combined with Salbutamol. |
Paliperidone | Paliperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Bortezomib | Bortezomib The metabolism of Imipramine can be decreased when combined with Bortezomib. |
Clofarabine Injection | Clofarabine Injection The serum concentration of Clofarabine can be increased when it is combined with Imipramine. |
Insulin Glulisine (rDNA origin) Injection | Insulin Glulisine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glulisine. |
Lubiprostone | Lubiprostone Imipramine may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
Oxaliplatin Injection | Oxaliplatin Injection The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine. |
Posaconazole | Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Imipramine. |
Primaquine | Primaquine The metabolism of Imipramine can be decreased when combined with Primaquine. |
Aliskiren | Aliskiren Imipramine may decrease the antihypertensive activities of Aliskiren. |
Bismuth Subsalicylate | Bismuth Subsalicylate Imipramine may increase the neurotoxic activities of Bismuth subsalicylate. |
Pemetrexed Injection | Pemetrexed Injection Imipramine may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
Dimenhydrinate | Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Lisdexamfetamine | Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Imipramine. |
Nabilone | Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Vorinostat | Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Imipramine. |
Sorafenib | Sorafenib The metabolism of Sorafenib can be decreased when combined with Imipramine. |
Sunitinib | Sunitinib The metabolism of Sunitinib can be decreased when combined with Imipramine. |
Dronabinol | Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Lapatinib | Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Imipramine. |
Levocetirizine | Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Pegaptanib Injection | Pegaptanib Injection Imipramine may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
Dasatinib | Dasatinib The metabolism of Dasatinib can be decreased when combined with Imipramine. |
Mexiletine | Mexiletine The metabolism of Imipramine can be decreased when combined with Mexiletine. |
Armodafinil | Armodafinil The metabolism of Imipramine can be decreased when combined with Armodafinil. |
Azacitidine Injection | Azacitidine Injection Imipramine may decrease the excretion rate of Azacitidine which could result in a higher serum level. |
Paclitaxel (with polyoxyethylated castor oil) Injection | Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Imipramine. |
Temsirolimus | Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Imipramine. |
Lenalidomide | Lenalidomide Imipramine may decrease the excretion rate of Lenalidomide which could result in a higher serum level. |
Nilotinib | Nilotinib The metabolism of Imipramine can be decreased when combined with Nilotinib. |
Toremifene | Toremifene The serum concentration of Toremifene can be increased when it is combined with Imipramine. |
Budesonide | Budesonide Imipramine may decrease the excretion rate of Budesonide which could result in a higher serum level. |
Chloramphenicol Injection | Chloramphenicol Injection The metabolism of Imipramine can be decreased when combined with Chloramphenicol. |
Desmopressin | Desmopressin The risk or severity of hyponatremia and water intoxication can be increased when Imipramine is combined with Desmopressin. |
Betaine | Betaine The therapeutic efficacy of Imipramine can be decreased when used in combination with Glycine betaine. |
OnabotulinumtoxinA Injection | OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A. |
RimabotulinumtoxinB Injection | RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum Toxin Type B. |
Doripenem Injection | Doripenem Injection Imipramine may decrease the excretion rate of Doripenem which could result in a higher serum level. |
Etravirine | Etravirine The serum concentration of Etravirine can be decreased when it is combined with Imipramine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Imipramine. |
Desvenlafaxine | Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Imipramine. |
Cevimeline | Cevimeline The metabolism of Imipramine can be decreased when combined with Cevimeline. |
Nebivolol | Nebivolol The metabolism of Imipramine can be decreased when combined with Nebivolol. |
Tretinoin | Tretinoin The metabolism of Tretinoin can be decreased when combined with Imipramine. |
Bendamustine Injection | Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Imipramine. |
Flecainide | Flecainide The metabolism of Flecainide can be decreased when combined with Imipramine. |
Certolizumab Injection | Certolizumab Injection The metabolism of Imipramine can be increased when combined with Certolizumab pegol. |
Irinotecan Injection | Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Imipramine. |
Daptomycin Injection | Daptomycin Injection Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Praziquantel | Praziquantel The metabolism of Praziquantel can be decreased when combined with Imipramine. |
Methylnaltrexone Injection | Methylnaltrexone Injection Imipramine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
Rufinamide | Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine. |
Silodosin | Silodosin Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Midazolam | Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Naltrexone Injection | Naltrexone Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Naltrexone. |
Dexrazoxane Injection | Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Eltrombopag | Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Imipramine. |
Milnacipran | Milnacipran The risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran. |
Dexlansoprazole | Dexlansoprazole The metabolism of Imipramine can be decreased when combined with Dexlansoprazole. |
Plerixafor Injection | Plerixafor Injection Imipramine may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
Sodium Phosphate | Sodium Phosphate The risk or severity of seizure can be increased when Imipramine is combined with Sodium phosphate, monobasic. |
Fesoterodine | Fesoterodine The metabolism of Imipramine can be decreased when combined with Fesoterodine. |
Degarelix Injection | Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imipramine. |
Betaxolol | Betaxolol The metabolism of Imipramine can be decreased when combined with Betaxolol. |
Iloperidone | Iloperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone. |
Prasugrel | Prasugrel The metabolism of Prasugrel can be decreased when combined with Imipramine. |
Lacosamide | Lacosamide The metabolism of Imipramine can be decreased when combined with Lacosamide. |
Everolimus | Everolimus The metabolism of Imipramine can be decreased when combined with Everolimus. |
Tolvaptan (low blood sodium) | Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Dronedarone | Dronedarone Dronedarone may increase the QTc-prolonging activities of Imipramine. |
AbobotulinumtoxinA Injection | AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A. |
Pralatrexate Injection | Pralatrexate Injection Imipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Palonosetron Injection | Palonosetron Injection The metabolism of Imipramine can be decreased when combined with Palonosetron. |
Saxagliptin | Saxagliptin Imipramine may decrease the hypoglycemic activities of Saxagliptin. |
Telavancin Injection | Telavancin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Telavancin. |
Romidepsin Injection | Romidepsin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin. |
Tapentadol | Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Topotecan | Topotecan Imipramine may decrease the excretion rate of Topotecan which could result in a higher serum level. |
Golimumab Injection | Golimumab Injection The metabolism of Imipramine can be increased when combined with Golimumab. |
Pazopanib | Pazopanib The metabolism of Imipramine can be decreased when combined with Pazopanib. |
Asenapine | Asenapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine. |
Vigabatrin | Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Albendazole | Albendazole The metabolism of Albendazole can be decreased when combined with Imipramine. |
Oxymorphone | Oxymorphone The metabolism of Imipramine can be decreased when combined with Oxymorphone. |
Liraglutide Injection | Liraglutide Injection Imipramine may decrease the hypoglycemic activities of Liraglutide. |
Tocilizumab Injection | Tocilizumab Injection The metabolism of Imipramine can be increased when combined with Tocilizumab. |
Dalfampridine | Dalfampridine The risk or severity of seizure can be increased when Imipramine is combined with Dalfampridine. |
Fingolimod | Fingolimod The metabolism of Fingolimod can be decreased when combined with Imipramine. |
Eribulin Injection | Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Imipramine. |
IncobotulinumtoxinA Injection | IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A. |
Cabazitaxel Injection | Cabazitaxel Injection The serum concentration of Imipramine can be increased when it is combined with Cabazitaxel. |
Ceftaroline Injection | Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Lurasidone | Lurasidone Imipramine may increase the hypotensive activities of Lurasidone. |
Acetaminophen Injection | Acetaminophen Injection Imipramine may increase the hepatotoxic activities of Acetaminophen. |
Vilazodone | Vilazodone The metabolism of Vilazodone can be decreased when combined with Imipramine. |
Ipilimumab Injection | Ipilimumab Injection Imipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
Denileukin Diftitox Injection | Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Terbutaline Injection | Terbutaline Injection The therapeutic efficacy of Imipramine can be decreased when used in combination with Terbutaline. |
Azilsartan | Azilsartan The risk or severity of adverse effects can be increased when Imipramine is combined with Azilsartan medoxomil. |
Roflumilast | Roflumilast Imipramine may decrease the excretion rate of Roflumilast which could result in a higher serum level. |
Linagliptin | Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Imipramine. |
Rilpivirine | Rilpivirine The metabolism of Imipramine can be decreased when combined with Rilpivirine. |
Telaprevir | Telaprevir The serum concentration of Imipramine can be increased when it is combined with Glecaprevir. |
Potassium Iodide | Potassium Iodide The risk or severity of Cardiac Arrhythmia can be increased when Potassium Iodide is combined with Imipramine. |
Cyclophosphamide Injection | Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Imipramine. |
Abiraterone | Abiraterone The serum concentration of Imipramine can be increased when it is combined with Abiraterone. |
Triptorelin Injection | Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imipramine. |
Rivaroxaban | Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Imipramine. |
Ticagrelor | Ticagrelor The serum concentration of Imipramine can be increased when it is combined with Ticagrelor. |
Ruxolitinib | Ruxolitinib Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. |
Vandetanib | Vandetanib The serum concentration of Vandetanib can be increased when it is combined with Imipramine. |
Clobazam | Clobazam The metabolism of Imipramine can be decreased when combined with Clobazam. |
Vemurafenib | Vemurafenib The serum concentration of Imipramine can be increased when it is combined with Vemurafenib. |
Vismodegib | Vismodegib The metabolism of Imipramine can be decreased when combined with Vismodegib. |
Ivacaftor | Ivacaftor The serum concentration of Imipramine can be increased when it is combined with Ivacaftor. |
Deferiprone | Deferiprone Imipramine may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
Axitinib | Axitinib The metabolism of Imipramine can be decreased when combined with Axitinib. |
Crizotinib | Crizotinib The serum concentration of Imipramine can be increased when it is combined with Crizotinib. |
Cabergoline | Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Naloxone Injection | Naloxone Injection Imipramine may decrease the excretion rate of Naloxone which could result in a higher serum level. |
Ambrisentan | Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Imipramine. |
Fondaparinux Injection | Fondaparinux Injection Imipramine may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
Ezogabine | Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Carfilzomib Injection | Carfilzomib Injection The serum concentration of Imipramine can be increased when it is combined with Carfilzomib. |
Iloprost | Iloprost The risk or severity of adverse effects can be increased when Imipramine is combined with Iloprost. |
Enzalutamide | Enzalutamide The serum concentration of Imipramine can be increased when it is combined with Enzalutamide. |
Mirabegron | Mirabegron The risk or severity of urinary retention can be increased when Imipramine is combined with Mirabegron. |
Regorafenib | Regorafenib The serum concentration of Imipramine can be increased when it is combined with Regorafenib. |
Linaclotide | Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Imipramine. |
Teriflunomide | Teriflunomide The serum concentration of Imipramine can be decreased when it is combined with Teriflunomide. |
Lorcaserin | Lorcaserin Imipramine may decrease the hypoglycemic activities of Mecasermin. |
Teduglutide Injection | Teduglutide Injection Imipramine may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
Bedaquiline | Bedaquiline The risk or severity of QTc prolongation can be increased when Imipramine is combined with Bedaquiline. |
Alogliptin | Alogliptin The metabolism of Imipramine can be decreased when combined with Alogliptin. |
Ponatinib | Ponatinib The metabolism of Imipramine can be decreased when combined with Ponatinib. |
Pomalidomide | Pomalidomide The metabolism of Imipramine can be decreased when combined with Pomalidomide. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The serum concentration of Imipramine can be increased when it is combined with Trastuzumab emtansine. |
Apixaban | Apixaban The metabolism of Imipramine can be decreased when combined with Apixaban. |
Canagliflozin | Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Imipramine. |
Methazolamide | Methazolamide Methazolamide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Dabrafenib | Dabrafenib The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib. |
Ospemifene | Ospemifene The metabolism of Imipramine can be decreased when combined with Ospemifene. |
Trametinib | Trametinib Imipramine may decrease the excretion rate of Trametinib which could result in a higher serum level. |
Dolutegravir | Dolutegravir The serum concentration of Imipramine can be increased when it is combined with Dolutegravir. |
Afatinib | Afatinib The serum concentration of Imipramine can be increased when it is combined with Afatinib. |
Levomilnacipran | Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Imipramine. |
Ertapenem Injection | Ertapenem Injection Ertapenem may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Vortioxetine | Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Imipramine. |
Perampanel | Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Ibrutinib | Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Imipramine. |
Lomitapide | Lomitapide The serum concentration of Imipramine can be increased when it is combined with Lomitapide. |
Avanafil | Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Imipramine. |
Ketorolac Injection | Ketorolac Injection Imipramine may decrease the excretion rate of Ketorolac which could result in a higher serum level. |
Obinutuzumab Injection | Obinutuzumab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab. |
Simeprevir | Simeprevir The serum concentration of Imipramine can be increased when it is combined with Simeprevir. |
Sofosbuvir | Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Imipramine. |
Dapagliflozin | Dapagliflozin The metabolism of Imipramine can be decreased when combined with Dapagliflozin. |
Apremilast | Apremilast The metabolism of Apremilast can be increased when combined with Imipramine. |
Droxidopa | Droxidopa Imipramine may increase the vasopressor activities of Droxidopa. |
Ceritinib | Ceritinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ceritinib. |
Siltuximab Injection | Siltuximab Injection The metabolism of Imipramine can be increased when combined with Siltuximab. |
Albiglutide Injection | Albiglutide Injection Imipramine may decrease the hypoglycemic activities of Albiglutide. |
Eslicarbazepine | Eslicarbazepine The metabolism of Imipramine can be decreased when combined with Eslicarbazepine. |
Belinostat Injection | Belinostat Injection The metabolism of Imipramine can be increased when combined with Belinostat. |
Idelalisib | Idelalisib The serum concentration of Imipramine can be increased when it is combined with Idelalisib. |
Testosterone Injection | Testosterone Injection The metabolism of Testosterone can be decreased when combined with Imipramine. |
Oritavancin Injection | Oritavancin Injection The metabolism of Imipramine can be decreased when combined with Oritavancin. |
Empagliflozin | Empagliflozin Imipramine may decrease the hypoglycemic activities of Empagliflozin. |
Vorapaxar | Vorapaxar The serum concentration of Imipramine can be increased when it is combined with Vorapaxar. |
Hydrocodone | Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Suvorexant | Suvorexant Imipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
Dulaglutide Injection | Dulaglutide Injection Imipramine may decrease the hypoglycemic activities of Dulaglutide. |
Edoxaban | Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Imipramine. |
Peginterferon Beta-1a Injection | Peginterferon Beta-1a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon beta-1a. |
Olaparib | Olaparib The metabolism of Imipramine can be increased when combined with Olaparib. |
Methamphetamine | Methamphetamine Metamfetamine may decrease the sedative and stimulatory activities of Imipramine. |
Tasimelteon | Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Riociguat | Riociguat Imipramine may decrease the antihypertensive activities of Riociguat. |
Pirfenidone | Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Imipramine. |
Nintedanib | Nintedanib The serum concentration of Imipramine can be increased when it is combined with Nintedanib. |
Secukinumab Injection | Secukinumab Injection The metabolism of Imipramine can be increased when combined with Secukinumab. |
Risperidone Injection | Risperidone Injection Imipramine may increase the hypotensive activities of Risperidone. |
Palbociclib | Palbociclib The serum concentration of Imipramine can be increased when it is combined with Palbociclib. |
Insulin Human Inhalation | Insulin Human Inhalation The metabolism of Imipramine can be increased when combined with Insulin human. |
Lenvatinib | Lenvatinib The metabolism of Imipramine can be decreased when combined with Lenvatinib. |
Naloxegol | Naloxegol The metabolism of Imipramine can be decreased when combined with Naloxegol. |
Panobinostat | Panobinostat The metabolism of Imipramine can be decreased when combined with Panobinostat. |
Dinutuximab Injection | Dinutuximab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab. |
Haloperidol Injection | Haloperidol Injection The serum concentration of Haloperidol can be increased when it is combined with Imipramine. |
Ivabradine | Ivabradine Ivabradine may increase the QTc-prolonging activities of Imipramine. |
Amiloride | Amiloride Amiloride may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Isavuconazonium Injection | Isavuconazonium Injection The serum concentration of Imipramine can be increased when it is combined with Isavuconazonium. |
Macitentan | Macitentan Imipramine may decrease the excretion rate of Macitentan which could result in a higher serum level. |
Flibanserin | Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Imipramine. |
Rolapitant | Rolapitant The metabolism of Imipramine can be decreased when combined with Rolapitant. |
Daclatasvir | Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Imipramine. |
Brexpiprazole | Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Imipramine. |
Ziprasidone Injection | Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Imipramine. |
Cariprazine | Cariprazine The metabolism of Cariprazine can be decreased when combined with Imipramine. |
Penicillin G Procaine Injection | Penicillin G Procaine Injection Imipramine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
Eluxadoline | Eluxadoline The risk or severity of constipation can be increased when Imipramine is combined with Eluxadoline. |
Insulin Degludec (rDNA Origin) Injection | Insulin Degludec (rDNA Origin) Injection The metabolism of Imipramine can be increased when combined with Insulin degludec. |
Cobimetinib | Cobimetinib The serum concentration of Imipramine can be increased when it is combined with Cobimetinib. |
Trabectedin Injection | Trabectedin Injection The metabolism of Imipramine can be decreased when combined with Trabectedin. |
Osimertinib | Osimertinib The serum concentration of Imipramine can be decreased when it is combined with Osimertinib. |
Ixazomib | Ixazomib Imipramine may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
Rifapentine | Rifapentine The metabolism of Imipramine can be increased when combined with Rifapentine. |
Lesinurad | Lesinurad Imipramine may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
Amphotericin B Liposomal Injection | Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Dexamethasone Injection | Dexamethasone Injection The metabolism of Imipramine can be increased when combined with Dexamethasone. |
Brivaracetam Injection | Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Venetoclax | Venetoclax The serum concentration of Imipramine can be increased when it is combined with Venetoclax. |
Cobicistat | Cobicistat The serum concentration of Imipramine can be increased when it is combined with Cobicistat. |
Midodrine | Midodrine Midodrine may increase the vasopressor activities of Imipramine. |
Selexipag | Selexipag The serum concentration of Selexipag can be increased when it is combined with Imipramine. |
Pimavanserin | Pimavanserin The risk or severity of adverse effects can be increased when Imipramine is combined with Pimavanserin. |
Obeticholic Acid | Obeticholic Acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Imipramine. |
Diphenhydramine Injection | Diphenhydramine Injection The metabolism of Imipramine can be decreased when combined with Diphenhydramine. |
Furosemide Injection | Furosemide Injection Imipramine may decrease the excretion rate of Furosemide which could result in a higher serum level. |
Rucaparib | Rucaparib The metabolism of Imipramine can be decreased when combined with Rucaparib. |
Lixisenatide Injection | Lixisenatide Injection Imipramine may decrease the hypoglycemic activities of Lixisenatide. |
Ribociclib | Ribociclib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ribociclib. |
Doxepin (Insomnia) | Doxepin (Insomnia) Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin. |
Plecanatide | Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Imipramine. |
Deutetrabenazine | Deutetrabenazine The metabolism of Imipramine can be decreased when combined with Deutetrabenazine. |
Valbenazine | Valbenazine The metabolism of Imipramine can be decreased when combined with Valbenazine. |
Safinamide | Safinamide The metabolism of Imipramine can be decreased when combined with Safinamide. |
Naldemedine | Naldemedine Imipramine may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
Midostaurin | Midostaurin The metabolism of Imipramine can be decreased when combined with Midostaurin. |
Neratinib | Neratinib The serum concentration of Imipramine can be increased when it is combined with Neratinib. |
Enasidenib | Enasidenib The metabolism of Imipramine can be decreased when combined with Enasidenib. |
Inotuzumab Ozogamicin Injection | Inotuzumab Ozogamicin Injection The serum concentration of Imipramine can be increased when it is combined with Inotuzumab ozogamicin. |
Benznidazole | Benznidazole Imipramine may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
Copanlisib Injection | Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Imipramine. |
Delafloxacin | Delafloxacin The risk or severity of QTc prolongation can be increased when Imipramine is combined with Delafloxacin. |
Betrixaban | Betrixaban The serum concentration of Imipramine can be increased when it is combined with Betrixaban. |
Letermovir | Letermovir The metabolism of Imipramine can be decreased when combined with Letermovir. |
Semaglutide Injection | Semaglutide Injection Imipramine may decrease the hypoglycemic activities of Semaglutide. |
Tetrabenazine | Tetrabenazine The metabolism of Imipramine can be decreased when combined with Tetrabenazine. |
Ertugliflozin | Ertugliflozin Imipramine may decrease the hypoglycemic activities of Ertugliflozin. |
Buprenorphine Injection | Buprenorphine Injection Imipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Apalutamide | Apalutamide The serum concentration of Imipramine can be increased when it is combined with Apalutamide. |
Fostamatinib | Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Imipramine. |
Avatrombopag | Avatrombopag The serum concentration of Imipramine can be increased when it is combined with Avatrombopag. |
Baricitinib | Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Imipramine. |
Lofexidine | Lofexidine The therapeutic efficacy of Imipramine can be increased when used in combination with Lofexidine. |
Plazomicin Injection | Plazomicin Injection Imipramine may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
Eliglustat | Eliglustat The metabolism of Eliglustat can be decreased when combined with Imipramine. |
Encorafenib | Encorafenib The metabolism of Imipramine can be decreased when combined with Encorafenib. |
Binimetinib | Binimetinib The metabolism of Binimetinib can be decreased when combined with Imipramine. |
Ivosidenib | Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Imipramine. |
Lusutrombopag | Lusutrombopag The serum concentration of Imipramine can be increased when it is combined with Lusutrombopag. |
Elagolix | Elagolix The metabolism of Imipramine can be decreased when combined with Elagolix. |
Tafenoquine | Tafenoquine The metabolism of Imipramine can be decreased when combined with Tafenoquine. |
Cannabidiol | Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Imipramine. |
Dacomitinib | Dacomitinib The metabolism of Imipramine can be decreased when combined with Dacomitinib. |
Duvelisib | Duvelisib The serum concentration of Imipramine can be increased when it is combined with Duvelisib. |
Omadacycline | Omadacycline The serum concentration of Imipramine can be increased when it is combined with Omadacycline. |
Sarecycline | Sarecycline The serum concentration of Imipramine can be increased when it is combined with Sarecycline. |
Stiripentol | Stiripentol The metabolism of Imipramine can be decreased when combined with Stiripentol. |
Talazoparib | Talazoparib The serum concentration of Imipramine can be increased when it is combined with Talazoparib. |
Gilteritinib | Gilteritinib The therapeutic efficacy of Imipramine can be decreased when used in combination with Gilteritinib. |
Glasdegib | Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Imipramine. |
Lorlatinib | Lorlatinib The metabolism of Imipramine can be decreased when combined with Lorlatinib. |
Larotrectinib | Larotrectinib The serum concentration of Imipramine can be increased when it is combined with Larotrectinib. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Imipramine. |
Rifamycin | Rifamycin The serum concentration of Imipramine can be increased when it is combined with Rifamycin. |
Prucalopride | Prucalopride Imipramine may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
Magnesium Citrate | Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Imipramine. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The metabolism of Imipramine can be increased when combined with Emapalumab. |
Siponimod | Siponimod The risk or severity of hypertension can be increased when Imipramine is combined with Siponimod. |
Acyclovir Ophthalmic | Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Imipramine. |
Erdafitinib | Erdafitinib The serum concentration of Imipramine can be increased when it is combined with Erdafitinib. |
Esomeprazole Injection | Esomeprazole Injection The metabolism of Imipramine can be decreased when combined with Esomeprazole. |
Alpelisib | Alpelisib The metabolism of Imipramine can be decreased when combined with Alpelisib. |
Brexanolone Injection | Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Solriamfetol | Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Imipramine. |
Darolutamide | Darolutamide The serum concentration of Imipramine can be increased when it is combined with Darolutamide. |
Triclabendazole | Triclabendazole The metabolism of Imipramine can be decreased when combined with Triclabendazole. |
Entrectinib | Entrectinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib. |
Istradefylline | Istradefylline The metabolism of Istradefylline can be decreased when combined with Imipramine. |
Pitolisant | Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Imipramine. |
Fedratinib | Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Imipramine. |
Lefamulin | Lefamulin Lefamulin may increase the QTc-prolonging activities of Imipramine. |
Phenytoin Injection | Phenytoin Injection The metabolism of Phenytoin can be decreased when combined with Imipramine. |
Fosphenytoin Injection | Fosphenytoin Injection The metabolism of Imipramine can be increased when combined with Fosphenytoin. |
Enfortumab vedotin-ejfv Injection | Enfortumab vedotin-ejfv Injection The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin. |
Zanubrutinib | Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Imipramine. |
Voxelotor | Voxelotor The metabolism of Voxelotor can be decreased when combined with Imipramine. |
Lumateperone | Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Lasmiditan | Lasmiditan The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Lasmiditan. |
Ubrogepant | Ubrogepant The serum concentration of Imipramine can be increased when it is combined with Ubrogepant. |
Tazemetostat | Tazemetostat The serum concentration of Imipramine can be increased when it is combined with Tazemetostat. |
Cenobamate | Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Imipramine. |
Selumetinib | Selumetinib The metabolism of Selumetinib can be decreased when combined with Imipramine. |
Rimegepant | Rimegepant The serum concentration of Imipramine can be increased when it is combined with Rimegepant. |
Tucatinib | Tucatinib The metabolism of Tucatinib can be decreased when combined with Imipramine. |
Remdesivir Injection | Remdesivir Injection The serum concentration of Imipramine can be increased when it is combined with Remdesivir. |
Ripretinib | Ripretinib The serum concentration of Imipramine can be increased when it is combined with Ripretinib. |
Selpercatinib | Selpercatinib The risk or severity of hypertension can be increased when Imipramine is combined with Selpercatinib. |
Capmatinib | Capmatinib The serum concentration of Imipramine can be increased when it is combined with Capmatinib. |
Lemborexant | Lemborexant The serum concentration of Imipramine can be decreased when it is combined with Lemborexant. |
Daratumumab and Hyaluronidase-fihj Injection | Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine. |
Fenfluramine | Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Imipramine. |
Fostemsavir | Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Imipramine. |
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine. |
Octreotide | Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine. |
Belantamab Mafodotin-blmf Injection | Belantamab Mafodotin-blmf Injection The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin. |
Pralsetinib | Pralsetinib The serum concentration of Imipramine can be increased when it is combined with Pralsetinib. |
Opicapone | Opicapone The metabolism of Imipramine can be increased when combined with Opicapone. |
Satralizumab-mwge Injection | Satralizumab-mwge Injection The serum concentration of Imipramine can be decreased when it is combined with Satralizumab. |
Naxitamab-gqgk Injection | Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Imipramine is combined with Naxitamab. |
Relugolix | Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Imipramine. |
Progestin-Only (drospirenone) Oral Contraceptives | Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Viloxazine | Viloxazine The metabolism of Imipramine can be decreased when combined with Viloxazine. |
Tobramycin Injection | Tobramycin Injection Tobramycin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Theophylline | Theophylline The metabolism of Imipramine can be decreased when combined with Theophylline. |
Fenoprofen | Fenoprofen Imipramine may decrease the excretion rate of Fenoprofen which could result in a higher serum level. |
Indomethacin | Indomethacin The metabolism of Imipramine can be decreased when combined with Indomethacin. |
Mefenamic Acid | Mefenamic Acid Imipramine may decrease the excretion rate of Mefenamic acid which could result in a higher serum level. |
Naproxen | Naproxen The metabolism of Naproxen can be decreased when combined with Imipramine. |
Tolmetin | Tolmetin Imipramine may decrease the excretion rate of Tolmetin which could result in a higher serum level. |
Sulindac | Sulindac Imipramine may decrease the excretion rate of Sulindac which could result in a higher serum level. |
Trazodone | Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imipramine. |
Isotretinoin | Isotretinoin Imipramine may decrease the excretion rate of Isotretinoin which could result in a higher serum level. |
Sucralfate | Sucralfate Sucralfate may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Hydroxyurea | Hydroxyurea The metabolism of Imipramine can be decreased when combined with Hydroxyurea. |
Floxuridine | Floxuridine Floxuridine may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Phenobarbital | Phenobarbital The metabolism of Imipramine can be decreased when combined with Phenobarbital. |
Metaxalone | Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Methotrexate Injection | Methotrexate Injection Methotrexate may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Levorphanol | Levorphanol The risk or severity of adverse effects can be increased when Imipramine is combined with Levorphanol. |
Primidone | Primidone The metabolism of Imipramine can be increased when combined with Primidone. |
Methsuximide | Methsuximide The metabolism of Methsuximide can be decreased when combined with Imipramine. |
Diethylpropion | Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Imipramine. |
Chlorpromazine | Chlorpromazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine. |
Diazepam | Diazepam The metabolism of Imipramine can be decreased when combined with Diazepam. |
Oxazepam | Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Flurazepam | Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Clorazepate | Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Lorazepam | Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Phenoxybenzamine | Phenoxybenzamine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine. |
Carmustine | Carmustine The metabolism of Carmustine can be decreased when combined with Imipramine. |
Amantadine | Amantadine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Amantadine. |
Codeine | Codeine The metabolism of Imipramine can be decreased when combined with Codeine. |
Meprobamate | Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine. |
Chlordiazepoxide | Chlordiazepoxide The risk or severity of adverse effects can be increased when Imipramine is combined with Chlordiazepoxide. |
Bromocriptine | Bromocriptine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Metaproterenol | Metaproterenol The risk or severity of hypertension can be increased when Imipramine is combined with Orciprenaline. |
Tranylcypromine | Tranylcypromine The metabolism of Tranylcypromine can be decreased when combined with Imipramine. |
Phenelzine | Phenelzine The metabolism of Imipramine can be decreased when combined with Phenelzine. |
Procarbazine | Procarbazine Procarbazine may increase the serotonergic activities of Imipramine. |
Ergoloid Mesylates | Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Tetracycline | Tetracycline Imipramine may decrease the excretion rate of Tetracycline which could result in a higher serum level. |
Minocycline | Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Prochlorperazine | Prochlorperazine The metabolism of Imipramine can be decreased when combined with Prochlorperazine. |
Thioridazine | Thioridazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioridazine. |
Trifluoperazine | Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Bleomycin | Bleomycin Bleomycin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Dapsone | Dapsone The metabolism of Imipramine can be decreased when combined with Dapsone. |
Sulfadiazine | Sulfadiazine Imipramine may decrease the hypoglycemic activities of Sulfadiazine. |
Oxycodone | Oxycodone The metabolism of Imipramine can be decreased when combined with Oxycodone. |
Methadone | Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Imipramine. |
Oxybutynin | Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Imipramine. |
Benztropine | Benztropine The metabolism of Imipramine can be decreased when combined with Benzatropine. |
Maprotiline | Maprotiline The metabolism of Maprotiline can be decreased when combined with Imipramine. |
Ibuprofen | Ibuprofen Imipramine may decrease the excretion rate of Ibuprofen which could result in a higher serum level. |
Trihexyphenidyl | Trihexyphenidyl Imipramine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl. |
Orphenadrine | Orphenadrine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
Perphenazine | Perphenazine The metabolism of Perphenazine can be decreased when combined with Imipramine. |
Azathioprine | Azathioprine The metabolism of Azathioprine can be decreased when combined with Imipramine. |
Fluphenazine | Fluphenazine The serum concentration of Imipramine can be increased when it is combined with Fluphenazine. |
Phentermine | Phentermine Phentermine may decrease the sedative and stimulatory activities of Imipramine. |
Methylphenidate | Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine. |
Amoxapine | Amoxapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine. |
Sulfasalazine | Sulfasalazine Imipramine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. |
Hydrocortisone | Hydrocortisone The metabolism of Imipramine can be increased when combined with Hydrocortisone. |
Doxorubicin | Doxorubicin The metabolism of Imipramine can be decreased when combined with Doxorubicin. |
Mechlorethamine | Mechlorethamine The therapeutic efficacy of Imipramine can be decreased when used in combination with Mechlorethamine. |
Dactinomycin | Dactinomycin The serum concentration of Imipramine can be increased when it is combined with Dactinomycin. |
Pyridostigmine | Pyridostigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Pyridostigmine. |
Phenazopyridine | Phenazopyridine Phenazopyridine may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Carbamazepine | Carbamazepine The metabolism of Imipramine can be increased when combined with Carbamazepine. |
Molindone | Molindone The risk or severity of adverse effects can be increased when Imipramine is combined with Molindone. |
Methyldopa | Methyldopa The therapeutic efficacy of Methyldopa can be decreased when used in combination with Imipramine. |
Clonidine | Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Imipramine. |
Prazosin | Prazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin. |
Hydralazine | Hydralazine Imipramine may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
Cimetidine | Cimetidine The metabolism of Imipramine can be decreased when combined with Cimetidine. |
Gentamicin Injection | Gentamicin Injection Gentamicin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Warfarin | Warfarin The metabolism of Warfarin can be decreased when combined with Imipramine. |
Clonazepam | Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Loperamide | Loperamide The metabolism of Imipramine can be decreased when combined with Loperamide. |
Promethazine | Promethazine The metabolism of Imipramine can be decreased when combined with Promethazine. |
Meclofenamate | Meclofenamate Imipramine may decrease the excretion rate of Meclofenamic acid which could result in a higher serum level. |
Nitrofurantoin | Nitrofurantoin Imipramine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Griseofulvin | Griseofulvin The metabolism of Imipramine can be increased when combined with Griseofulvin. |
Digoxin | Digoxin Digoxin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Loxapine | Loxapine The serum concentration of Imipramine can be increased when it is combined with Loxapine. |
Chloroquine | Chloroquine The metabolism of Imipramine can be decreased when combined with Chloroquine. |
Quinine | Quinine The metabolism of Imipramine can be decreased when combined with Quinine. |
Ethosuximide | Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Triamterene | Triamterene The metabolism of Triamterene can be decreased when combined with Imipramine. |
Lactulose | Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Imipramine. |
Sulfinpyrazone | Sulfinpyrazone The metabolism of Imipramine can be increased when combined with Sulfinpyrazone. |
Chlorothiazide | Chlorothiazide Imipramine may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy. |
Chlorthalidone | Chlorthalidone Imipramine may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy. |
Metolazone | Metolazone Imipramine may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy. |
Isosorbide | Isosorbide Isosorbide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Clindamycin Injection | Clindamycin Injection Imipramine may increase the neurotoxic activities of Clindamycin. |
Secobarbital | Secobarbital The metabolism of Imipramine can be increased when combined with Secobarbital. |
Desipramine | Desipramine The metabolism of Desipramine can be decreased when combined with Imipramine. |
Amitriptyline | Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Imipramine. |
Probenecid | Probenecid The metabolism of Imipramine can be decreased when combined with Probenecid. |
Quinidine | Quinidine Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Procainamide | Procainamide The metabolism of Procainamide can be decreased when combined with Imipramine. |
Isoniazid | Isoniazid The metabolism of Imipramine can be decreased when combined with Isoniazid. |
Pyrazinamide | Pyrazinamide Pyrazinamide may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Rifampin | Rifampin The serum concentration of Imipramine can be decreased when it is combined with Rifampicin. |
Disopyramide | Disopyramide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide. |
Valproic Acid | Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imipramine. |
Tamoxifen | Tamoxifen The metabolism of Imipramine can be decreased when combined with Tamoxifen. |
Butabarbital | Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Levothyroxine | Levothyroxine The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Imipramine. |
Liothyronine | Liothyronine The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Imipramine. |
Methimazole | Methimazole The risk or severity of Cardiac Arrhythmia can be increased when Methimazole is combined with Imipramine. |
Propylthiouracil | Propylthiouracil The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Imipramine. |
Chlorpropamide | Chlorpropamide Imipramine may decrease the hypoglycemic activities of Chlorpropamide. |
Glucagon Injection | Glucagon Injection Imipramine may increase the gastrointestinal motility reducing activities of Glucagon. |
Tolbutamide | Tolbutamide Imipramine may decrease the hypoglycemic activities of Tolbutamide. |
Tolazamide | Tolazamide Imipramine may decrease the hypoglycemic activities of Tolazamide. |
Dextromethorphan | Dextromethorphan The metabolism of Imipramine can be decreased when combined with Dextromethorphan. |
Cyclobenzaprine | Cyclobenzaprine The risk or severity of CNS depression can be increased when Imipramine is combined with Cyclobenzaprine. |
Niacin | Niacin The metabolism of Imipramine can be decreased when combined with Niacin. |
Baclofen | Baclofen The risk or severity of CNS depression and hypotonia can be increased when Baclofen is combined with Imipramine. |
Doxylamine | Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Cyproheptadine | Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Imipramine. |
Clemastine | Clemastine The metabolism of Imipramine can be decreased when combined with Clemastine. |
Chlorpheniramine | Chlorpheniramine The metabolism of Imipramine can be decreased when combined with Chlorpheniramine. |
Brompheniramine | Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Meclizine | Meclizine The metabolism of Imipramine can be decreased when combined with Meclizine. |
Ethambutol | Ethambutol Ethambutol may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Methyclothiazide | Methyclothiazide Methyclothiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Hydrochlorothiazide | Hydrochlorothiazide Imipramine may decrease the excretion rate of Hydrochlorothiazide which could result in a higher serum level. |
Dantrolene | Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Chlorzoxazone | Chlorzoxazone The metabolism of Imipramine can be decreased when combined with Chlorzoxazone. |
Carisoprodol | Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine. |
Methocarbamol | Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Pyridoxine | Pyridoxine Pyridoxine may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Folic Acid | Folic Acid Folic acid may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Disulfiram | Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Imipramine. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Imipramine. |
Minoxidil | Minoxidil Imipramine may decrease the antihypertensive activities of Minoxidil. |
Pseudoephedrine | Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Imipramine. |
Nortriptyline | Nortriptyline Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline. |
Spironolactone | Spironolactone Spironolactone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy. |
Amphotericin B Injection | Amphotericin B Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Phytonadione | Phytonadione Imipramine may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
Amikacin Injection | Amikacin Injection Amikacin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Nadolol | Nadolol The metabolism of Imipramine can be decreased when combined with Nadolol. |
Butorphanol Injection | Butorphanol Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Butorphanol. |
Nalbuphine Injection | Nalbuphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Nalbuphine. |
Allopurinol | Allopurinol Allopurinol may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Oxytocin Injection | Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine. |
Trimethobenzamide | Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Clomiphene | Clomiphene The serum concentration of Imipramine can be increased when it is combined with Clomifene. |
Flavoxate | Flavoxate Imipramine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. |
Papaverine | Papaverine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Papaverine. |
Fluorouracil Injection | Fluorouracil Injection The metabolism of Fluorouracil can be decreased when combined with Imipramine. |
Colchicine | Colchicine The metabolism of Imipramine can be decreased when combined with Colchicine. |
Cefaclor | Cefaclor Cefaclor may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cefadroxil | Cefadroxil Cefadroxil may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cefazolin Injection | Cefazolin Injection Cefazolin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cephalexin | Cephalexin Cephalexin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cefoxitin Injection | Cefoxitin Injection Cefoxitin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Dacarbazine | Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Imipramine. |
Acetazolamide | Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Cefotaxime Injection | Cefotaxime Injection Cefotaxime may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Calcitonin Salmon Injection | Calcitonin Salmon Injection The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Imipramine. |
Ketoconazole | Ketoconazole The metabolism of Imipramine can be decreased when combined with Ketoconazole. |
Pyrantel | Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Thiotepa Injection | Thiotepa Injection The metabolism of Imipramine can be decreased when combined with Thiotepa. |
Vincristine Injection | Vincristine Injection The metabolism of Vincristine can be decreased when combined with Imipramine. |
Captopril | Captopril Imipramine may decrease the antihypertensive activities of Captopril. |
Dipyridamole | Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Imipramine. |
Isoxsuprine | Isoxsuprine The risk or severity of hypertension can be increased when Imipramine is combined with Isoxsuprine. |
Vinblastine | Vinblastine The metabolism of Imipramine can be decreased when combined with Vinblastine. |
Ethacrynic Acid | Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Colistimethate Injection | Colistimethate Injection Colistimethate may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Metoprolol | Metoprolol The metabolism of Imipramine can be decreased when combined with Metoprolol. |
Hydroxyzine | Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Imipramine. |
Thiothixene | Thiothixene The risk or severity of adverse effects can be increased when Imipramine is combined with Thiothixene. |
Aspirin | Aspirin The metabolism of Acetylsalicylic acid can be increased when combined with Imipramine. |
Salsalate | Salsalate Imipramine may decrease the excretion rate of Salsalate which could result in a higher serum level. |
Alprazolam | Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Temazepam | Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Triazolam | Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Dicyclomine | Dicyclomine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine. |
Hyoscyamine | Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imipramine. |
Propantheline | Propantheline Imipramine may increase the central nervous system depressant (CNS depressant) activities of Propantheline. |
Trimethoprim | Trimethoprim Trimethoprim may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Diltiazem | Diltiazem The metabolism of Imipramine can be decreased when combined with Diltiazem. |
Nifedipine | Nifedipine The metabolism of Imipramine can be decreased when combined with Nifedipine. |
Timolol | Timolol The metabolism of Timolol can be decreased when combined with Imipramine. |
Verapamil | Verapamil Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil. |
Atenolol | Atenolol The metabolism of Imipramine can be decreased when combined with Atenolol. |
Pindolol | Pindolol The metabolism of Imipramine can be decreased when combined with Pindolol. |
Cisplatin Injection | Cisplatin Injection The serum concentration of Cisplatin can be increased when it is combined with Imipramine. |
Diflunisal | Diflunisal Imipramine may decrease the excretion rate of Diflunisal which could result in a higher serum level. |
Piroxicam | Piroxicam Imipramine may decrease the excretion rate of Piroxicam which could result in a higher serum level. |
Bumetanide | Bumetanide Bumetanide may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Streptozocin | Streptozocin The metabolism of Imipramine can be increased when combined with Streptozocin. |
Etoposide | Etoposide The metabolism of Etoposide can be decreased when combined with Imipramine. |
Glyburide | Glyburide The metabolism of Glyburide can be decreased when combined with Imipramine. |
Glipizide | Glipizide Imipramine may decrease the hypoglycemic activities of Glipizide. |
Indapamide | Indapamide Imipramine may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy. |
Amoxicillin | Amoxicillin Imipramine may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
Nafcillin Injection | Nafcillin Injection The metabolism of Imipramine can be increased when combined with Nafcillin. |
Oxacillin Injection | Oxacillin Injection Imipramine may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
Pentoxifylline | Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Imipramine. |
Pentamidine Injection | Pentamidine Injection The metabolism of Imipramine can be decreased when combined with Pentamidine. |
Ceftriaxone Injection | Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Labetalol | Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Auranofin | Auranofin Imipramine may decrease the excretion rate of Auranofin which could result in a higher serum level. |
Leuprolide Injection | Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine. |
Gemfibrozil | Gemfibrozil The metabolism of Imipramine can be decreased when combined with Gemfibrozil. |
Guanabenz | Guanabenz The risk or severity of hypertension can be increased when Imipramine is combined with Guanabenz. |
Dipivefrin Ophthalmic | Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Ceftazidime Injection | Ceftazidime Injection Ceftazidime may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Ketoprofen | Ketoprofen Imipramine may decrease the excretion rate of Ketoprofen which could result in a higher serum level. |
Cefotetan Injection | Cefotetan Injection Cefotetan may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Pimozide | Pimozide The metabolism of Pimozide can be decreased when combined with Imipramine. |
Enalapril | Enalapril Imipramine may decrease the antihypertensive activities of Enalapril. |
Flurbiprofen | Flurbiprofen Imipramine may decrease the excretion rate of Flurbiprofen which could result in a higher serum level. |
Amiodarone | Amiodarone The serum concentration of Imipramine can be increased when it is combined with Amiodarone. |
Aztreonam Injection | Aztreonam Injection Aztreonam may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Buspirone | Buspirone The metabolism of Buspirone can be decreased when combined with Imipramine. |
Lovastatin | Lovastatin The metabolism of Imipramine can be decreased when combined with Lovastatin. |
Ciprofloxacin | Ciprofloxacin The metabolism of Imipramine can be decreased when combined with Ciprofloxacin. |
Mesalamine | Mesalamine Mesalazine may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Diclofenac | Diclofenac The metabolism of Diclofenac can be decreased when combined with Imipramine. |
Fluoxetine | Fluoxetine The serum concentration of Fluoxetine can be increased when it is combined with Imipramine. |
Nimodipine | Nimodipine The risk or severity of hypotension can be increased when Imipramine is combined with Nimodipine. |
Interferon Alfa-2b Injection | Interferon Alfa-2b Injection The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b. |
Clozapine | Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Estazolam | Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Idarubicin | Idarubicin The metabolism of Imipramine can be decreased when combined with Idarubicin. |
Ofloxacin | Ofloxacin The metabolism of Imipramine can be decreased when combined with Ofloxacin. |
Didanosine | Didanosine Imipramine may decrease the excretion rate of Didanosine which could result in a higher serum level. |
Pentostatin Injection | Pentostatin Injection Imipramine may decrease the excretion rate of Pentostatin which could result in a higher serum level. |
Clarithromycin | Clarithromycin The serum concentration of Clarithromycin can be increased when it is combined with Imipramine. |
Benazepril | Benazepril Imipramine may decrease the antihypertensive activities of Benazepril. |
Etodolac | Etodolac Imipramine may decrease the excretion rate of Etodolac which could result in a higher serum level. |
Felodipine | Felodipine The metabolism of Imipramine can be decreased when combined with Felodipine. |
Fosinopril | Fosinopril Imipramine may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
Nabumetone | Nabumetone The metabolism of Nabumetone can be decreased when combined with Imipramine. |
Pravastatin | Pravastatin The serum concentration of Imipramine can be increased when it is combined with Pravastatin. |
Quinapril | Quinapril Imipramine may decrease the antihypertensive activities of Quinapril. |
Ramipril | Ramipril Imipramine may decrease the antihypertensive activities of Ramipril. |
Simvastatin | Simvastatin The metabolism of Simvastatin can be decreased when combined with Imipramine. |
Amlodipine | Amlodipine The risk or severity of hypotension can be increased when Imipramine is combined with Amlodipine. |
Teniposide Injection | Teniposide Injection The metabolism of Imipramine can be decreased when combined with Teniposide. |
Itraconazole | Itraconazole The serum concentration of Imipramine can be increased when it is combined with Itraconazole. |
Lisinopril | Lisinopril Imipramine may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
Oxaprozin | Oxaprozin Imipramine may decrease the excretion rate of Oxaprozin which could result in a higher serum level. |
Rifabutin | Rifabutin The metabolism of Imipramine can be increased when combined with Rifabutin. |
Sotalol | Sotalol The metabolism of Sotalol can be decreased when combined with Imipramine. |
Bisoprolol | Bisoprolol Imipramine may increase the orthostatic hypotensive activities of Bisoprolol. |
Zolpidem | Zolpidem Zolpidem may increase the Decreased alertness activities of Imipramine. |
Doxazosin | Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Terazosin | Terazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin. |
Isradipine | Isradipine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Isradipine. |
Omeprazole | Omeprazole The metabolism of Imipramine can be decreased when combined with Omeprazole. |
Cisapride | Cisapride The metabolism of Imipramine can be decreased when combined with Cisapride. |
Gabapentin | Gabapentin The risk or severity of adverse effects can be increased when Imipramine is combined with Gabapentin. |
Fluvastatin | Fluvastatin The metabolism of Imipramine can be decreased when combined with Fluvastatin. |
Venlafaxine | Venlafaxine The metabolism of Imipramine can be decreased when combined with Venlafaxine. |
Nizatidine | Nizatidine The therapeutic efficacy of Imipramine can be decreased when used in combination with Nizatidine. |
Stavudine | Stavudine Imipramine may increase the neurotoxic activities of Stavudine. |
Fluvoxamine | Fluvoxamine The metabolism of Imipramine can be decreased when combined with Fluvoxamine. |
Nefazodone | Nefazodone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone. |
Lamotrigine | Lamotrigine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine. |
Losartan | Losartan The metabolism of Imipramine can be decreased when combined with Losartan. |
Valacyclovir | Valacyclovir Valaciclovir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Tramadol | Tramadol The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Tramadol. |
Vinorelbine Injection | Vinorelbine Injection The metabolism of Imipramine can be decreased when combined with Vinorelbine. |
Carboplatin Injection | Carboplatin Injection Carboplatin may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Moexipril | Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Imipramine. |
Lansoprazole | Lansoprazole The metabolism of Imipramine can be decreased when combined with Lansoprazole. |
Ifosfamide Injection | Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Imipramine. |
Nicardipine | Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Bupropion | Bupropion The risk or severity of seizure can be increased when Bupropion is combined with Imipramine. |
Ticlopidine | Ticlopidine The metabolism of Imipramine can be decreased when combined with Ticlopidine. |
Saquinavir | Saquinavir The serum concentration of Imipramine can be increased when it is combined with Saquinavir. |
Metformin | Metformin Imipramine may decrease the hypoglycemic activities of Metformin. |
Nisoldipine | Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Imipramine. |
Lamivudine | Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Imipramine. |
Riluzole | Riluzole The metabolism of Riluzole can be decreased when combined with Imipramine. |
Amifostine Injection | Amifostine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Amifostine. |
Acarbose | Acarbose Imipramine may decrease the hypoglycemic activities of Acarbose. |
Glimepiride | Glimepiride Imipramine may decrease the hypoglycemic activities of Glimepiride. |
Gemcitabine Injection | Gemcitabine Injection The serum concentration of Imipramine can be increased when it is combined with Gemcitabine. |
Indinavir | Indinavir The metabolism of Imipramine can be decreased when combined with Indinavir. |
Ritonavir | Ritonavir The serum concentration of Imipramine can be increased when it is combined with Ritonavir. |
Docetaxel Injection | Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Imipramine. |
Cidofovir Injection | Cidofovir Injection Cidofovir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Meropenem Injection | Meropenem Injection Imipramine may decrease the excretion rate of Meropenem which could result in a higher serum level. |
Clomipramine | Clomipramine The metabolism of Clomipramine can be decreased when combined with Imipramine. |
Zafirlukast | Zafirlukast The metabolism of Imipramine can be decreased when combined with Zafirlukast. |
Fosfomycin | Fosfomycin Imipramine may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
Mirtazapine | Mirtazapine Imipramine may increase the serotonergic activities of Mirtazapine. |
Trandolapril | Trandolapril Imipramine may decrease the antihypertensive activities of Trandolapril. |
Topiramate | Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Imipramine is combined with Topiramate. |
Zileuton | Zileuton The metabolism of Zileuton can be decreased when combined with Imipramine. |
Valsartan | Valsartan Imipramine may decrease the antihypertensive activities of Valsartan. |
Insulin Lispro Injection | Insulin Lispro Injection The metabolism of Imipramine can be increased when combined with Insulin lispro. |
Pramipexole | Pramipexole Imipramine may increase the sedative activities of Pramipexole. |
Donepezil | Donepezil The therapeutic efficacy of Imipramine can be decreased when used in combination with Donepezil. |
Nelfinavir | Nelfinavir The metabolism of Imipramine can be decreased when combined with Nelfinavir. |
Fexofenadine | Fexofenadine The serum concentration of Imipramine can be increased when it is combined with Fexofenadine. |
Azithromycin | Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Imipramine. |
Loratadine | Loratadine Imipramine may increase the anticholinergic activities of Loratadine. |
Carvedilol | Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Nilutamide | Nilutamide The metabolism of Imipramine can be decreased when combined with Nilutamide. |
Flutamide | Flutamide The metabolism of Flutamide can be decreased when combined with Imipramine. |
Selegiline | Selegiline The metabolism of Selegiline can be decreased when combined with Imipramine. |
Bicalutamide | Bicalutamide The metabolism of Imipramine can be decreased when combined with Bicalutamide. |
Sertraline | Sertraline The metabolism of Sertraline can be decreased when combined with Imipramine. |
Propafenone | Propafenone The metabolism of Imipramine can be decreased when combined with Propafenone. |
Letrozole | Letrozole The metabolism of Imipramine can be decreased when combined with Letrozole. |
Raloxifene | Raloxifene The metabolism of Imipramine can be decreased when combined with Raloxifene. |
Irbesartan | Irbesartan Imipramine may decrease the antihypertensive activities of Irbesartan. |
Tamsulosin | Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine. |
Ropinirole | Ropinirole The risk or severity of adverse effects can be increased when Imipramine is combined with Ropinirole. |
Finasteride | Finasteride The metabolism of Finasteride can be decreased when combined with Imipramine. |
Quetiapine | Quetiapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine. |
Cefepime Injection | Cefepime Injection Cefepime may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cefprozil | Cefprozil Cefprozil may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cefpodoxime | Cefpodoxime Cefpodoxime may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Cetirizine | Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Paroxetine | Paroxetine The metabolism of Paroxetine can be decreased when combined with Imipramine. |
Tolcapone | Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Citalopram | Citalopram Imipramine may increase the QTc-prolonging activities of Citalopram. |
Capecitabine | Capecitabine Imipramine may decrease the excretion rate of Capecitabine which could result in a higher serum level. |
Efavirenz | Efavirenz The metabolism of Imipramine can be increased when combined with Efavirenz. |
Abacavir | Abacavir Imipramine may decrease the excretion rate of Abacavir which could result in a higher serum level. |
Sildenafil | Sildenafil The metabolism of Imipramine can be decreased when combined with Sildenafil. |
Pioglitazone | Pioglitazone Imipramine may decrease the hypoglycemic activities of Pioglitazone. |
Celecoxib | Celecoxib The metabolism of Imipramine can be decreased when combined with Celecoxib. |
Rosiglitazone | Rosiglitazone The metabolism of Imipramine can be decreased when combined with Rosiglitazone. |
Tolterodine | Tolterodine The metabolism of Imipramine can be decreased when combined with Tolterodine. |
Thalidomide | Thalidomide Imipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
Oseltamivir | Oseltamivir Oseltamivir may decrease the excretion rate of Imipramine which could result in a higher serum level. |
Balsalazide | Balsalazide Imipramine may decrease the excretion rate of Balsalazide which could result in a higher serum level. |
Nateglinide | Nateglinide The metabolism of Imipramine can be decreased when combined with Nateglinide. |
Galantamine | Galantamine The metabolism of Imipramine can be decreased when combined with Galantamine. |
Levetiracetam | Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine. |
Rabeprazole | Rabeprazole The metabolism of Imipramine can be decreased when combined with Rabeprazole. |
Terbinafine | Terbinafine The metabolism of Imipramine can be decreased when combined with Terbinafine. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists